By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Danish pharmaceutical company Novo Nordisk has expanded its presence in Thailand by reopening its renovated and enlarged ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.

The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said. Novo Nordisk - which ...

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...